Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma

L Max Almond, Alessandro Gronchi, Dirk Strauss, Mariam Jafri, Samuel Ford, Anant Desai

Research output: Contribution to journalReview articlepeer-review


Extended surgery remains the mainstay of treatment in retroperitoneal sarcoma, although conflicting data exist on the benefit of neoadjuvant and adjuvant therapies, particularly with regard to tumour grade and histological type. Experience of radiotherapy and chemotherapy in extremity soft tissue sarcoma can inform treatment strategies, however these data cannot be universally extrapolated to the retroperitoneum where disease biology and anatomical considerations are different. The present review sets a historical context before discussing recent evidence and on-going multi-centre trials in retroperitoneal sarcoma. Promising data on histologically- and molecularly-targeted chemotherapy are discussed and the need for centralisation of retroperitoneal sarcoma services in order to facilitate large international collaborative trials is emphasised.

Original languageEnglish
Pages (from-to)571-579
Number of pages9
JournalEuropean Journal of Surgical Oncology
Issue number5
Publication statusPublished - May 2018


  • Chemotherapy, Adjuvant
  • Humans
  • Neoadjuvant Therapy
  • Radiotherapy, Adjuvant
  • Retroperitoneal Neoplasms/therapy
  • Sarcoma/therapy


Dive into the research topics of 'Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma'. Together they form a unique fingerprint.

Cite this